ArticleAnnals of hematology2025
Long-term follow-up of autologous hematopoietic cell transplantation for diffuse large B cell lymphoma in the rituximab era: real‑world data from a retrospective single‑center analysis.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Autologous stem cell transplantation (ASCT) is the standard treatment for diffuse large B-cell lymphoma (DLBCL) in certain circumstances. However, the risk factors for ASCT outcomes remain elusive. We analyzed data from 141 patients with DLBCL who underwent first ASCT in the past decade, including 19 with pre-existing autoimmune disorders (ADs). We focus on the clinical characteristics and their potential predictive roles for the long-term transplant prognosis. With a median follow-up of 50 months (interquartile range, 26.3 to 128), progression-free survival (PFS) and overall survival (OS) at 3 years were 82.8% and 90.2%, respectively. Deaths after ASCT were predominantly caused by lymphoma relapse (73.3%). Notably, ADs history was independently associated with an increased risk of all-cause mortality (Hazard Ratio [HR]: 8.38, P = 0.014) and lymphoma relapse (HR: 6.67, P = 0.026). Furthermore, disease status before ASCT, COO subtypes, lactate dehydrogenase level at diagnosis and relapse after chemotherapy were also identified as prognostic factors for both PFS and OS. These findings demonstrate ASCT as a viable treatment option for eligible patients with high-risk DLBCL and highlight the need for increased attention to lymphoma with pre-ADs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.